Abstract
ABSTRACT New inventions can increase productivity, accelerate the creation of new profits, and provide lucrative growth potential. Using a fixed effect model, this article examines the influence of government innovation subsidies and tax rebates on the R&D production of pharmaceutical companies from 2010 to 2020. It also assesses the moderators of institutional investors, audit agencies, and public opinion in monitoring. The research finds that government innovation subsidies and tax rebates have a significant impact on pharmaceutical enterprises’ R&D outputs. Second, institutional shareholding and public opinion supervision can increase government innovation subsidies and tax breaks for pharmaceutical R&D. SOEs are more susceptible to innovation subsidies, while non-SOEs benefit from tax rebates. This study assists managers and policymakers develop effective innovation strategies.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
